At the last check on Thursday, Takeda Pharmaceutical Company Limited’s (NYSE:TAK) stock was down -$0.35, moving down -2.18 percent to $15.94. The average number of shares traded per day over the past five days has been 1,321,385 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.34 fall in that time frame. In the last twenty days, the average volume was 1,553,041, while in the previous 50 days, it was 2,225,336.
Since last month, TAK stock rose 5.95%. Shares of the company fell to $15.04 on 08/22/23, the lowest level in the past month. A 52-week high of $17.15 was reached on 04/06/23 after having rallying from a 52-week low of $12.28. Since the beginning of this year, TAK’s stock price has risen by 2.15% or $0.35, and marked a new high 11 times. However, the stock has declined by -7.08% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, Takeda Pharmaceutical Company Limited (TAK) has a P/E ratio of about 24.48. The stock’s beta is 0.63. Besides these, the trailing price-to-sales (P/S) ratio of 1.80, the price-to-book (PB) ratio of 1.06.
Financial Health
In the recent quarter, Takeda Pharmaceutical Company Limited’s quick ratio stood at 0.60, while its current ratio was 1.00, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 0.63, and the total debt-to-equity ratio was 0.69. On the profitability front, the trailing twelve-month gross margin is 69.10% percent. In the recent year, EBITDA margin amounted to 32.84%, whereas operating margins totaled 12.40%. Based on annual data, TAK earned $20.6 billion in gross profit and brought in $29.8 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.00%. Return on equity (ROE) for the past 12 months was 4.60%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TAK’s revenue rose 100.0% during the quarter, while net income inched up to $27.9 billion. During the quarter, the company generated $2.48 billion in EBITDA. The liabilities of Takeda Pharmaceutical Company Limited were 57.46 billion at the end of its most recent quarter, and its total debt was $5.24 trillion.
Technical Picture
This quick technical analysis looks at Takeda Pharmaceutical Company Limited’s (TAK) price momentum. With a historical volatility rate of 19.61%, the RSI 9-day stood at 56.38% on 20 September.
With respect to its five-day moving average, the current Takeda Pharmaceutical Company Limited price is down by -2.06% percent or -$0.34. At present, TAK shares trade +4.76% above its 20-day simple moving average and -3.83% percent below its 100-day simple moving average. However, the stock is currently trading approximately +2.34% above its SMA50 and +7.66% above its SMA200.
Stochastic coefficient K was 84.03% and Stochastic coefficient D was 91.22%, while ATR was 0.19. Given the Stochastic reading of 65.34% for the 14-day period, the RSI (14) reading has been calculated as 58.70%. As of today, the MACD Oscillator reading stands at 0.10, while the 14-day reading stands at 0.39.
Analyst Ratings
BofA Securities upgraded its rating on Takeda Pharmaceutical Company Limited (NYSE: TAK) to a Buy in a note to investors on March 16, 2023. The analysts firm previously had a Neutral rating on the stock.Takeda Pharmaceutical Company Limited (TAK) has been rated Overweight by analysts. According to 0 brokerage firms, TAK is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Takeda Pharmaceutical Company Limited stock as buy, with 6 recommending it as overweight.
With a median target price of $16.43, the current consensus forecast for the stock is $12.80 – $20.67. Based on these forecasts, analysts predict Takeda Pharmaceutical Company Limited (TAK) will achieve an average price target of $16.52.
